Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Session Type:

CME Eligible Sessions:

Availability:

Showing session: reset

HIV Reservoirs and Cure Strategies

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 10 of 10
A Posttranscriptional Block Limits HIV Env Expression in Reactivated Cells From PWH on ART   (ABSTRACT 133)
Jonathan Richard
Centre de Recherche du CHUM, Montreal, Canada
from CROI 2026 on February 24, 2026 10:00 AM-12:00 PM
Altered Viral Kinetics at ATI After Dual LS-bNAbs Plus ART: A Preliminary Analysis of RIO Arm B   (ABSTRACT 134)
Julia Edgar
University of Oxford, Oxford, UK
from CROI 2026 on February 24, 2026 10:00 AM-12:00 PM
Autologous Neutralising Antibodies and Effective CD8 T Cells Maintain HIV Postintervention Control   (ABSTRACT 135)
Katie Fisher
Aarhus University, Aarhus, Denmark
from CROI 2026 on February 24, 2026 10:00 AM-12:00 PM
Bacteria-Specific CD4+ T Cells Contribute to HIV Persistence During ART   (ABSTRACT 136)
Armando Espinosa Ortiz
Université de Montréal, Montreal, Canada
from CROI 2026 on February 24, 2026 10:00 AM-12:00 PM
Questions and Answers (Part 1)
from CROI 2026 on February 24, 2026 10:00 AM-12:00 PM
CD4-Targeted IL-15 Enhanced bNAb Activity and Improved SHIV Control After Treatment Interruption   (ABSTRACT 137)
Jeffrey Murry
Gilead Sciences, Inc, Foster City, CA, USA
from CROI 2026 on February 24, 2026 10:00 AM-12:00 PM
Decoding the Somatic Mutation Landscape in Persisting HIV-1-Infected CD4+ T Clones   (ABSTRACT 138)
Marie Armani-Tourret
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
from CROI 2026 on February 24, 2026 10:00 AM-12:00 PM
Ibalizumab-Targeted Delivery of Tat mRNA Transactivates Provirus Expression In Vivo   (ABSTRACT 139)
Edward F. Kreider
University of Pennsylvania, Philadelphia, PA, USA
from CROI 2026 on February 24, 2026 10:00 AM-12:00 PM
Immune-Mediated Viral Control With Budigalimab ± Trosunilimab: First Results of Phase II Global RCT   (ABSTRACT 140)
Ana Gabriela Pires Dos Santos
AbbVie, Inc, North Chicago, IL, USA
from CROI 2026 on February 24, 2026 10:00 AM-12:00 PM
Questions and Answers (Part 2)
from CROI 2026 on February 24, 2026 10:00 AM-12:00 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 10 of 10